• Oligodendrocyte and myelin-axonal degeneration
• Neurovascular and blood–brain barrier dysfunction
• Neuroimmune signaling in Alzheimer’s disease and related disorders
• Advanced tool development: Multi-modal integration of proteomics and imaging, iPSC-based disease modeling and AAV tool development
Uncovering vulnerability of the myelin-axon unit in Alzheimer's disease
In Alzheimer’s disease (AD), myelin–axon interface, axon–glial signaling, paranodal architecture and amyloid-β aggregation are altered, implicating myelin–axon disruption in disease progression.
Deciphering molecular mechanisms of axonal pathology in Alzheimer’s’ disease
Integration of subcellular proximity labeling proteomics in human postmortem brains, and molecular manipulation in human iPSC-derived AD model and AD-model mice, we aim to to uncover mechanisms of axonal pathology in Alzheimer’s disease
Decode competing endogenous RNA (ceRNA) regulation in Alzheimer's disease
Long non-coding RNA, microRNA and mRNA regulation network and hierachy
Generation and analysis of SETD1A-deficient human neurons in schizophrenia
Protein targets of Setd1a strongly correlate to schizophrenia Genome-Wide Association Study signals